Jinwon Life Sciences Selects JP Morgan as Lead Manager for Subsidiary VGXI Fundraising
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 2nd that its subsidiary VGXI has selected JP Morgan as the lead underwriter to raise funds through equity.
The company stated, "VGXI is currently constructing a new Plant 1 in Conroe, Texas, USA, and plans to complete construction and qualification evaluation in the first quarter of next year."
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Wallets Open Wide on Big News...300 Trillion Won Heads to the U.S., "Tax Breaks" Fail to Keep Funds at Home
- "Realizing How Fast Money Disappears: Should You Try Only the Essentials for 5,000 Won? [The Basics of Benefits]"
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
It added, "The funds raised this time will be invested in building a new Plant 2 to maximize the production capacity of plasmid DNA and mRNA, which have recently seen a surge in demand, and we are also promoting the construction of a new Plant 3."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
